A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases

NCT04460729 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped company decision

Conditions

Non-small Cell Lung Carcinoma (NSCLC)

Interventions

DRUG: Capmatinib

Sponsor

Novartis Pharmaceuticals